Avasa is developing the Avasa Coupler, a category‑defining device that enables safe, fast and standardized reconnection of micro‑arteries used in reconstructive microsurgery. The company has reached design freeze and built pre‑production units that achieved 100% success in chronic animal studies. Founder and CEO Dr. Nandoun Abeysekera is a clinician‑bioengineer and Avasa reports strong clinical demand—89% of the 100+ microsurgeons interviewed expressed strong interest. Founded in 2018 and based in Auckland, New Zealand, Avasa is completing verification testing and recruiting commercial leadership to build its go‑to‑market strategy. The company intends to use the new capital to progress through FDA clearance and to launch commercially within the next 18 months. Avasa, led by CEO and founder Dr. Nandoun Abeysekera, is an Auckland, New Zealand-based medical device company focused on innovating surgical procedures through implantable devices. The company’s core product targets reconstructive microsurgery to help patients who have suffered debilitating disease and deformity. Avasa raised $1.55M in funding and intends to use the proceeds to expand operations. The announcement lists participation from both new and existing investors. Dr. Abeysekera expects the scope of the company’s device to expand into other surgical fields, including organ transplants, cardiothoracic surgery, and vascular surgery. The coverage was reported by FInSMEs on 14 September 2023.

Total raised

$4M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2025